SAN FRANCISCO, June 28, 2017 /PRNewswire/ -- Audentes
Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company
focused on developing and commercializing gene therapy products for
patients living with serious, life-threatening rare diseases, today
announced its participation in the following upcoming investor
conferences:
- Piper Jaffray GenomeRx Symposium
Panel: Gene Therapy – Tackling Manufacturing
July 11, 2017, 11:20 am ET
The Lotte New York Palace, New
York
- Wedbush PacGrow Healthcare Conference
Corporate Presentation
August 15, 2017, 12:45 pm ET
Le Parker Meridien Hotel, New
York
To access a live webcast of the corporate presentation at the
Wedbush PacGrow Healthcare Conference, please visit the Events
& Presentations page within the Investors & News section of
the Audentes website. A replay of the live webcast will be
available on the Audentes website for approximately 30 days
following the conference. There is no webcast available for
the Gene Therapy – Tackling Manufacturing panel at the Piper
Jaffray GenomeRx Symposium.
About Audentes Therapeutics, Inc.
Audentes
Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on
developing and commercializing gene therapy products for patients
living with serious, life-threatening rare diseases. We have
four product candidates in development, AT132 for the treatment of
X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of
Crigler-Najjar Syndrome, AT982 for the treatment of Pompe disease,
and AT307 for the treatment of the CASQ2 subtype of
Catecholaminergic Polymorphic Ventricular Tachycardia
(CASQ2-CPVT). We are a focused, experienced and passionate
team committed to forging strong, global relationships with the
patient, research and medical communities.
For more information regarding Audentes, please visit
www.audentestx.com.
Audentes Contacts:
Investor Contact:
Thomas Soloway, CFO
415.818.1040
ir@audentestx.com
Media Contact:
Paul Laland
415.519.6610
media@audentestx.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/audentes-therapeutics-announces-participation-in-upcoming-investor-conferences-300481008.html
SOURCE Audentes Therapeutics, Inc.